Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Today Multiplicom, ICAN and ICM announced they signed an agreement to jointly develop a new generation of molecular diagnostic tests to identify disease predisposition mutations in cardiovascular, metabolic and neurological diseases. Multiplicom’s expertise in the development of massive parallel sequencing based molecular diagnostics in combination with the disease specific knowledge and the availability of well documented samples at ICAN and ICM will lead to the development of innovative diagnostic tests that will help patients and their doctors to prevent and/or cure disease in an early stage.
Multiplicom is a Belgian diagnostics company, specialized in the design, development, production, and commercialization of innovative molecular genetic tests based on massive parallel sequencing. ICAN and ICM are two Hospital-University Institutes (IHU) at Hôpital Pitié Salpêtrière in Paris that are specialized in cardiovascular & metabolic and neurological diseases, respectively. Under the collaboration the parties will closely work together on a number of specific projects with the aim of developing and validating diagnostic tests for the identification of disease related mutations based on massive parallel sequencing. Multiplicom will be responsible for the commercialization of the resulting products. As a first project an early onset diabetes test will be developed, with additional projects following shortly thereafter.
“I’m delighted by the collaboration as it will allow to translate our world class science into routine tests that can contribute to improve diagnosis in our patients” said Pr. Karine Clément from ICAN.
“This collaboration joins together experts in academic research and industry to more rapidly advance research into routine clinical practice” added Bertrand Fontaine from IHU-A-ICM. “With this agreement Multiplicom demonstrates its commitment to partner with key opinion leaders in multiple disease areas to develop innovative products that meet real needs in the clinic” added Dirk Pollet, CEO of Multiplicom.
Multiplicom produces molecular diagnostic kits that enable clinical laboratories to perform profitable testing for personalized medicine. The company was created in 2011 as a spin-off by the University of Antwerp and VIB.
Multiplicom develops, manufactures and commercializes leading-edge and easy-to-use genetic test kits, based on the latest molecular diagnostic technologies. The successful introduction of its kits in medical genetics labs proves they are the solution to an increasing demand for nucleic acid based testing that is driven by the scientific evidence that links genetic information to health and disease.
ICM (Institut du Cerveau et de la Moelle epinière) and ICAN (Institute of Cardiométabolisme And Nutrition) are preeminent centers for translational medicine. ICM and ICAN both include a research center, a clinical research platform and a biotech incubator each of which brings together over 500 researchers and physicians focused on fundamental and translational research in neurology, and metabolism & nutrition, respectively, with a strong emphasis on industry partnerships. In 2010, ICM and ICAN were announced by the French Ministers of Health and Research as a laureate of the “Hospitalo-University Institute” program, which launched the framework of the “Investments for the Future”.